Interleukin 6 Receptor Blockade to Treat Chronic Active Antibody-Mediated Rejection in Kidney Transplant: A Case Report With Review of Relevant Literature

Author(s):  
Rajeev Sharma ◽  
Aidas J Mattis ◽  
Ayoola Adekile
2021 ◽  
pp. 1-3
Author(s):  
Victor Dominguez Prieto ◽  
Victor Dominguez Prieto ◽  
Cecilia Meliga ◽  
Sara Rosenstone ◽  
Siyuan Qian Zhang ◽  
...  

Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab.


2020 ◽  
pp. annrheumdis-2020-218243 ◽  
Author(s):  
Nicola Potere ◽  
Marcello Di Nisio ◽  
Donatella Cibelli ◽  
Rosa Scurti ◽  
Antonella Frattari ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document